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Abstract
Some haematological diseases are associated to an increased risk of thromboembolic events. We
report a case of paroxysmal nocturnal haemoglobinuria (PNH) in which a cerebrovascular event
represented the first clinical manifestation of disease. PNH is associated to thromboembolic events,
generally of venous districts often involving unusual locations such as mesenteric vessels, sagittal
veins, inferior vena cava and renal veins.
To our knowledge arterial thrombotic episodes are rare and the involvement of arterial cerebral
vessels is exceptional. Then, our case points out the importance of investigating about
haematological disorders in all patients presenting with a stroke, in which the common
predisposing conditions are excluded.
Background
Paroxysmal nocturnal haemoglobinuria (PNH) is an
acquired clonal disorder of haematopoietic stem cells
clinically characterized by acute intravascular haemolytic
crisis, in particular nocturnal, often overlapped to chronic
haemolysis, and by thrombotic events and bone marrow
failure. It is associated with a somatic mutation in the
phosphatidylinositol glycan complementation class A
(PIG-A) gene, mapped to the X chromosome; the subse-
quent deficiency of glycosylphosphatidylinositol (GPI)
and of GPI-anchored molecules, as the decay accelerating
factor (DAF or CD55) and the membrane inhibitor of
reactive lysis (MIRL or CD59), causes an increased suscep-
tibility to complement-mediated lysis of erythrocytes, leu-
kocytes and platelets [1].
The association between PNH and thromboembolic acci-
dents, generally manifesting as thrombotic events of
venous vessels sometimes complicated by pulmonary
embolism, is well established. Arterial thrombotic epi-
sodes, particularly of cerebral vessels are enough rare [2].
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We report a case of PNH presenting with thromboembolic
events, both venous (proximal deep venous thrombosis
of lower limbs) and arterial (stroke).
Case history
Clinical summary
A 56-year-old woman, with history of peptic ulcer and
family history for cerebrovascular disease was referred to
our Division of Internal Medicine with asthenia and gen-
eralized discomfort. She reported a cerebrovascular acci-
dent manifesting as a right brachial and crural
hyposthenia ten month ago, almost completely receded at
observation time; she also referred recurrent episodes of
proximal deep venous thrombosis (DVT) of lower limbs
in the last seven months.
Pathological findings
In order to identify any hypercoagulable state (i.e. inher-
ited or acquired thrombophilia), in view of her personal
and familiar history, we tested prothrombin time, as INR,
activated partial thromboplastin time, as ratio, fibrino-
gen, protein C and S, antithrombin III, activated protein C
resistance, anti-cardiolipin antibodies IgG and IgM, lupus
anticoagulant, plasminogen activator inhibitor type 1, d-
dimer, gene polimorphism of clotting factor II and V, gene
polimorphism C9774T and G3775A of apolipoprotein B
and gene polimorphism C3932T and C4070T of apolipo-
protein E resulted all in normal range; while gene poli-
morphism of tetrahydrofolate reductase and angiotensin
converting enzyme revealed heterozigosity for both. Sub-
sequently, homocysteinemia test revealed mild hyperho-
mocysteinemia. All thrombophilic tests are summarised
in table 1.
A magnetic resonance imaging scan showed little and
multiple ischemic lesions in particular in left cerebral
peduncle (fig 1A), semioval centres (fig 1B), left pons and
midbrain. Moreover, a vascular ultrasound examination
ruled out the presence of significant stenosis of arterial
Table 1: Thrombophilic tests
Thrombophilic tests (units of measurement) Results Normal range
Protein C (antigen) (%) 99% 60–125
Protein S (antigen) (%) 102% 60–125
Antithrombin (activity) (%) 105% 80–120
Activated protein C resistance (Bertina) 0,90 >0,77
Anti-cardiolipin antibodies IgG (U/GPL) 4 <7
Anti-cardiolipin antibodies IgM (U/MPL) 2 <4
Lupus anticoagulant absent absent
Plasminogen activator inhibitor type 1 (ng/dl) 30 4–44
PTHRA20210 gene polimorphism wild type wild type
Factor V Leiden gene polimorphism wild type wild type
Apolipoprotein B gene polimorphism C9774T and G3775A wild type wild type
Apolipoprotein E gene polimorphism C3932T and C4070T wild type wild type
Methylene-tetrahydrofolate C677T gene polimorphism heterozigosity wild type
Angiotensin converting enzyme deletion gene polimorphism insertion/deletion insertion/insertion
Homocysteinemia (µM) 22 5–15
Prothrombin time (INR) 0.95 0.8–1.2
Activated partial thromboplastin time (ratio) 0.92 0.8–1.2
Fibrinogen (mg/dl) 305 220–400
D-dimer (ug/l) 188 0–198
Magnetic resonance imaging scan showing multiple ischemic  lesions in left cerebral peduncle (1A) and semioval centres  (1B) Figure 1
Magnetic resonance imaging scan showing multiple ischemic 
lesions in left cerebral peduncle (1A) and semioval centres 
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cerebral vessels and confirmed proximal DVT and post-
thrombotic syndrome of lower limbs.
Other available data showed: red blood cells 2.470.000/
mm3, hemoglobin 7.9 g/dl, hematocrit 25%, mean cor-
puscular volume 99,6 fl, mean corpuscular hemoglobin
32 pg, mean corpuscular hemoglobin concentration 32
gr/dl, white blood cells 4,040/mm3, platelets 93.000/
mm3, reticulocytes 5,4%, serum iron 76 µg/dl, erytro-sed-
imentation rate 1° hour 40 mm, lactate dehydrogenase
944 UI/l, total bilirubin 0,72 mg/dl, indirect bilirubin
0,36 mg/dl, and presence of hemoglobinuria. Coombs'
test, cold agglutinins, antinuclear antibodies, anti-extract-
able nuclear antigens antibodies, anti-mithocondrial
antibodies, anti-smooth muscle antibodies were negative.
Laboratory data and their range are summarised in table
2.
An abdominal ultrasonography excluded a hypersplenism
and/or Kasabath-Merritt syndrome.
A peripheral blood smear did not show any finding sug-
gestive for haematological disorders. A bone marrow
biopsy showed a slight hyperplasia of erythrocytic bone
marrow cell line.
These laboratory and morphological findings suggested a
non-immune haemolytic anemia. In particular, due to the
exclusion of other non-immune haemolityc disorders by
means of age and clinical history together with the pres-
ence of hemoglobinuria and pancytopenia, we hypothe-
sized paroxysmal nocturnal hemoglobinuria. This
diagnosis was confirmed by an immunophenotypic pro-
file of peripheral blood cells, showing a 15% of deficient
CD59 erythrocytes, and by the presence of hemosiderinu-
ria. Haematological findings are summarised in table 3.
During her hospitalization two haemotrasfusions were
necessary in occasion of two concurrent haemolytic crises.
Following dismission, in order to prevent further throm-
boembolic events, the patient began oral anticoagulation
Table 2: Other laboratory findings
Laboratory data (units of measurement) Results Normal range
Erytro-sedimentation rate 1° hour (mm) 40 <10
lactate dehydrogenase (UI/l) 944 100–190
total bilirubin (mg/dl) 0,72 0–1
indirect bilirubin (mg/dl) 0,36 0–0,5
antinuclear antibodies absent absent
anti-extractable nuclear antigens antibodies absent absent
anti-mithocondrial antibodies absent absent
anti-smooth muscle antibodies absent absent
Table 3: Haematological data
Laboratory data (units of measurement) Results Normal range
red blood cells (cells/mm3) 2.470.000 4.200.000 – 5.400.000
hemoglobin (g/dl) 7,9 12–16
hematocrit (%) 25 37–45
mean corpuscolar volume (fl) 99,6 81–99
mean corpuscolar hemoglobin (pg) 32 27–31
mean corpuscolar hemoglobin concentration (g/dl) 32 32–36
white blood cells (cells/mm3) 4.040 4.800 – 10.800
Platelets (cells/mm3) 93.000 130.000 – 400.000
Reticulocytes (%) 5,4 <2
haemoblobinuria traces absent
Hemosiderinuria present absent
Coombs'test negative negative
cold agglutinins negative negative
Peripheral blood smear Normal
Bone marrow biopsy slight hyperplasia of erythrocytic cell line
Immunophenotypic profile of peripheral blood cells 15% of deficient CD59 erythrocytesThrombosis Journal 2004, 2:10 http://www.thrombosisjournal.com/content/2/1/10
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therapy with warfarin according with INR value in range
of 2–2,5. Moreover she was treated with B12 vitamin and
folate supplementation.
Discussion
The association between haematological diseases and
thromboembolic events is well established. In particular
high thrombotic risk is recognized in patients with essen-
tial thrombocythemia, polycythemia vera, PNH and
drepanocytosis [3]. PNH is associated to venous thrombo-
sis in approximately one third of cases. The most fre-
quently reported locations are unusual such as mesenteric
vessels, sagittal veins, inferior vena cava and renal veins.
When thrombosis occurs in the pre-hepatic or hepatic
veins, the patient develops a Budd-Chiari syndrome [4].
Arterial thrombosis is rare, even if few cases of cerebral
arterial thrombosis [5] and acute myocardial infarction
[6] are described in the literature.
The mechanism whereby PNH causes an hypercoagulable
state is not clear. PNH platelets lack the GPI-linked pro-
teins CD55 and CD59, and respond to the deposition of
terminal complement components by vesiculations of
portions of their plasma membrane, resulting an
increased procoagulant property. PNH cells also lack the
receptor of the GPI-linked urokinase plasminogen activa-
tor, which may result in impaired fibrinolysis [4]. Also an
increase of membrane-derived procoagulant microparti-
cles (phosphatidylserin) stemming from the platelets of
PNH patients has been described [3].
In our case, thrombotic events represented the clinical
onset of PNH and involved both venous (DVT) and arte-
rial (stroke) vessels. Neurological manifestations in PNH
patients are generally due to cerebral venous thrombosis
[7,8], even if a few cases of cerebral arterial episodes,
involving large vessels, are described. However, usually
cerebral ischaemia in PNH did not occur as presenting
sign of the disease nor affect small and middle
cerebrovascular arteries [5]. In our patient the relationship
between PNH and thrombotic events is strongly sug-
gested, especially after excluding inherited or acquired
thrombophilia and atherosclerotic risk factors. Hetero-
zigosities for gene polimorphism of tetrahydrofolate
reductase and angiotensin converting enzyme, detected in
our patient, are not associated to an increased risk of
stroke, while acquired or inherited hyperhomocysteine-
mia may be involved [9-11].
Also haemotological findings agree with PNH diagnosis
because of the association of thrombosis, anemia and
thrombocytopenia. We excluded further causes of non-
immune haemolityc anemia (i.e. spherocytosis, enzy-
matic disorders, microangiopathic anemia) and thrombo-
cytopenia (i.e. disseminated intravascular coagulation,
haematological malignancies, systemic erythematosus
lupus, primary or secondary antiphospholipid syndrome,
hypersplenism).
In conclusion, PNH is associated to thromboembolic
events, especially in the venous district and should be
considered as a possible cause of an hypercoagulable
state, in particular when unusual vascular locations are
involved. Our case indicates the possibility of arterial
thrombotic episodes in a patient with PNH and suggests a
thorough evaluation of any haematological disorders in
patients presenting with stroke or myocardial infarction,
especially in the absence of atherosclerosis risk factors
and/or a thrombophilic state.
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